Showing results (71-80 of 6,499) with videos related to
Sort By:
Pageof 650
Cancer Immunology, Immunotherapy : CII|September 3, 2010
Viral DNA contamination is responsible for Epstein-Barr virus detection in cytotoxic T lymphocytes stimulated in vitro with Epstein-Barr virus B-lymphoblastoid cell lineMathilde Berthomé, Géraldine Gallot, Régine Vivien, et al.Cancer Immunology, Immunotherapy : CII|December 15, 2010
Adenoviral-transduced dendritic cells are susceptible to suppression by T regulatory cells and promote interleukin 17 productionAdele Y Wang, Sarah Q Crome, Kristina M Jenkins, et al.Cancer Immunology, Immunotherapy : CII|January 1, 1990
Phase I/II study of recombinant interferon alpha and gamma in advanced progressive renal-cell carcinomaP H de Mulder, F M Debruyne, M P Franssen, et al.Cancer Immunology, Immunotherapy : CII|November 16, 2010
Development of a successful antitumor therapeutic model combining in vivo dendritic cell vaccination with tumor irradiation and intratumoral GM-CSF deliveryGregory Driessens, Lise Nuttin, Alain Gras, et al.Cancer Immunology, Immunotherapy : CII|November 6, 2010
Topoisomerase inhibitors modulate expression of melanocytic antigens and enhance T cell recognition of tumor cellsTimothy J Haggerty, Ian S Dunn, Lenora B Rose, et al.Cancer Immunology, Immunotherapy : CII|December 17, 2010
Determination of paraneoplastic autoimmune responses by tumor cell biology and intratumoral IFN-alpha/IL-12 in breast cancer patientsChristoph Domschke, Florian Schuetz, Yingzi Ge, et al.Cancer Immunology, Immunotherapy : CII|January 1, 1990
Antibody-penicillin-V-amidase conjugates kill antigen-positive tumor cells when combined with doxorubicin phenoxyacetamideD E Kerr, P D Senter, W V Burnett, et al.Cancer Immunology, Immunotherapy : CII|December 21, 2010
Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy)Anna Maria Di Giacomo, Riccardo Danielli, Luana Calabrò, et al.Cancer Immunology, Immunotherapy : CII|December 29, 2010
A peptidoglycan monomer with the glutamine to serine change and basic peptides bind in silico to TLR-2 (403-455)Yufeng Li, Clay L Efferson, Rajagopal Ramesh, et al.Cancer Immunology, Immunotherapy : CII|December 29, 2010
Physical and biological properties of homophilic therapeutic antibodiesAnn Jay Bryan, Heinz KohlerPageof 650